Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
48
GENSF Quote, Financials, Valuation and Earnings
Last price:
$35.15
Seasonality move
:
12.13%
Day range:
$35.15 - $35.15
52-week range:
$20.90 - $35.15
Dividend yield:
1.2%
P/E ratio:
93.91x
P/S ratio:
2.69x
P/B ratio:
3.38x
Volume:
--
Avg. volume:
--
1-year change:
68.17%
Market cap:
$2.3B
Revenue:
$870.4M
EPS (TTM):
$0.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GENSF
Genus Plc
|
-- | -- | -- | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GENSF
Genus Plc
|
$35.15 | -- | $2.3B | 93.91x | $0.29 | 1.2% | 2.69x |
|
APM
Aptorum Group Ltd.
|
$1.32 | -- | $9.4M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.55 | $9.52 | $412.5M | -- | $0.00 | 0% | 8.05x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$5.04 | $17.94 | $3.1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$4.17 | $104.00 | $17.4M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.74 | $7.99 | $206.8M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GENSF
Genus Plc
|
32.51% | 0.668 | -- | 1.26x |
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GENSF
Genus Plc
|
-- | -- | -0.51% | -0.73% | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Genus Plc vs. Competitors
-
Which has Higher Returns GENSF or APM?
Aptorum Group Ltd. has a net margin of -- compared to Genus Plc's net margin of --. Genus Plc's return on equity of -0.73% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GENSFGenus Plc-- -- $959.9M APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About GENSF or APM?
Genus Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 11263.64%. Given that Aptorum Group Ltd. has higher upside potential than Genus Plc, analysts believe Aptorum Group Ltd. is more attractive than Genus Plc.
Company Buy Ratings Hold Ratings Sell Ratings GENSFGenus Plc0 0 0 APMAptorum Group Ltd.0 0 0 -
Is GENSF or APM More Risky?
Genus Plc has a beta of 0.521, which suggesting that the stock is 47.871% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.612%.
-
Which is a Better Dividend Stock GENSF or APM?
Genus Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 1.2%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genus Plc pays 109.29% of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GENSF or APM?
Genus Plc quarterly revenues are --, which are smaller than Aptorum Group Ltd. quarterly revenues of --. Genus Plc's net income of -- is lower than Aptorum Group Ltd.'s net income of --. Notably, Genus Plc's price-to-earnings ratio is 93.91x while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genus Plc is 2.69x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GENSFGenus Plc2.69x 93.91x -- -- APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns GENSF or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Genus Plc's net margin of -373.3%. Genus Plc's return on equity of -0.73% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital GENSFGenus Plc-- -- $959.9M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About GENSF or AUTL?
Genus Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 514.34%. Given that Autolus Therapeutics Plc has higher upside potential than Genus Plc, analysts believe Autolus Therapeutics Plc is more attractive than Genus Plc.
Company Buy Ratings Hold Ratings Sell Ratings GENSFGenus Plc0 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is GENSF or AUTL More Risky?
Genus Plc has a beta of 0.521, which suggesting that the stock is 47.871% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock GENSF or AUTL?
Genus Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 1.2%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genus Plc pays 109.29% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GENSF or AUTL?
Genus Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Genus Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Genus Plc's price-to-earnings ratio is 93.91x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genus Plc is 2.69x versus 8.05x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GENSFGenus Plc2.69x 93.91x -- -- AUTLAutolus Therapeutics Plc8.05x -- $21.1M -$78.6M
-
Which has Higher Returns GENSF or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Genus Plc's net margin of --. Genus Plc's return on equity of -0.73% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital GENSFGenus Plc-- -- $959.9M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About GENSF or BDRX?
Genus Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3428.8%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Genus Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Genus Plc.
Company Buy Ratings Hold Ratings Sell Ratings GENSFGenus Plc0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is GENSF or BDRX More Risky?
Genus Plc has a beta of 0.521, which suggesting that the stock is 47.871% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock GENSF or BDRX?
Genus Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 1.2%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genus Plc pays 109.29% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GENSF or BDRX?
Genus Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Genus Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Genus Plc's price-to-earnings ratio is 93.91x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genus Plc is 2.69x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GENSFGenus Plc2.69x 93.91x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns GENSF or NCNA?
NuCana Plc has a net margin of -- compared to Genus Plc's net margin of --. Genus Plc's return on equity of -0.73% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital GENSFGenus Plc-- -- $959.9M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About GENSF or NCNA?
Genus Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 498700.96%. Given that NuCana Plc has higher upside potential than Genus Plc, analysts believe NuCana Plc is more attractive than Genus Plc.
Company Buy Ratings Hold Ratings Sell Ratings GENSFGenus Plc0 0 0 NCNANuCana Plc0 1 0 -
Is GENSF or NCNA More Risky?
Genus Plc has a beta of 0.521, which suggesting that the stock is 47.871% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock GENSF or NCNA?
Genus Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 1.2%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genus Plc pays 109.29% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GENSF or NCNA?
Genus Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Genus Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Genus Plc's price-to-earnings ratio is 93.91x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genus Plc is 2.69x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GENSFGenus Plc2.69x 93.91x -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns GENSF or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Genus Plc's net margin of --. Genus Plc's return on equity of -0.73% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GENSFGenus Plc-- -- $959.9M TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About GENSF or TLSA?
Genus Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 359.1%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Genus Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Genus Plc.
Company Buy Ratings Hold Ratings Sell Ratings GENSFGenus Plc0 0 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is GENSF or TLSA More Risky?
Genus Plc has a beta of 0.521, which suggesting that the stock is 47.871% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.
-
Which is a Better Dividend Stock GENSF or TLSA?
Genus Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 1.2%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genus Plc pays 109.29% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GENSF or TLSA?
Genus Plc quarterly revenues are --, which are smaller than Tiziana Life Sciences Ltd. quarterly revenues of --. Genus Plc's net income of -- is lower than Tiziana Life Sciences Ltd.'s net income of --. Notably, Genus Plc's price-to-earnings ratio is 93.91x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genus Plc is 2.69x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GENSFGenus Plc2.69x 93.91x -- -- TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
